Passage Bio to Participate in Upcoming October Investor Conferences
September 25 2020 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that management
will participate in two upcoming virtual investor conferences:
Jefferies 2020 Virtual Gene Therapy/Editing
SummitFormat: PresentationDate: Friday, October 2,
2020Time: 11 a.m. ET
Chardan 4th
Annual Genetic Medicines
ConferenceFormat: Fireside ChatDate: Monday, October 5,
2020Time: 1 p.m. ET
Live audio webcasts of the presentation and fireside chat will
be available on the Investors & Media section of Passage Bio’s
website at investors.passagebio.com. A replay of the webcasts will
be available for 30 days following the presentation and fireside
chat.
About Passage Bio Passage Bio
is a genetic medicines company focused on developing transformative
therapies for rare, monogenic central nervous system disorders with
limited or no approved treatment options. The company is based in
Philadelphia, PA and has a research, collaboration and license
agreement with the University of Pennsylvania and its Gene Therapy
Program (GTP). The GTP conducts discovery and IND-enabling
preclinical work and Passage Bio conducts all clinical development,
regulatory strategy and commercialization activities under the
agreement. The company has a development portfolio of six product
candidates, with the option to license eleven more, with lead
programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe
disease.
For further information, please contact:
Investors:Sarah McCabe and Zofia MitaStern Investor Relations,
Inc.sarah.mccabe@sternir.com zofia.mita@sternir.com
Media:Gwen FisherPassage
Bio215.407.1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2023 to Jul 2024